Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.24M | $10.7M | $10.3M | $5.80M | $8.19M | $4.41M | -$68.0K | $426K | $20.0K | $41.0K |
| Revenue growth | — | 231.8% | -3.8% | -43.8% | 41.1% | -46.1% | -101.5% | 726.5% | -95.3% | 105.0% |
| Operating income | -$11.1M | -$52.0M | -$42.8M | -$21.5M | -$54.8M | -$96.9M | -$87.7M | -$95.9M | -$103M | -$94.5M |
| Operating margin | -342.7% | -484.7% | -414.6% | -370.0% | -669.5% | -2197.6% | 129029.4% | -22518.5% | -515860.0% | -230461.0% |
| Net income | -$11.1M | -$46.4M | -$39.2M | -$20.5M | -$49.0M | -$97.1M | -$84.7M | -$88.4M | -$95.1M | -$88.1M |
| Net margin | -342.6% | -432.3% | -379.2% | -353.7% | -599.2% | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
| EPS (diluted) | $2.95 | -$118.91 | -$15.16 | -$1.60 | -$1.91 | -$2.35 | -$1.81 | -$1.66 | -$1.34 | -$1.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.35M | -$20.2M | -$9.39M | -$9.60M | -$34.3M | -$78.2M | -$62.6M | -$75.8M | -$79.8M | -$67.5M |
| Capital expenditures | $125K | $112K | $975K | $1.23K | $204K | $12.1M | $126K | $47.0K | — | $11.0K |
| Free cash flow | -$6.48M | -$20.3M | -$10.4M | -$9.60M | -$34.5M | -$90.4M | -$62.7M | -$75.9M | — | -$67.5M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.88M | $8.77M | $33.7M | $8.96M | $116M | $190M | $111M | $135M | $36.9M | $43.8M |
| Total assets | $38.4M | $63.0M | $54.8M | $54.1M | $245M | $219M | $207M | $211M | $139M | $280M |
| Total liabilities | $6.19M | $14.4M | $6.44M | $8.54M | $19.2M | $19.7M | $21.6M | $16.5M | $15.8M | $55.0M |
| Long-term debt | — | $600K | $1.85M | $1.86M | $1.83M | $1.45M | $4.58M | — | — | $34.3M |
| Shareholders' equity | $32.2M | $39.4M | $48.3M | $45.5M | $226M | $199M | $185M | $194M | $124M | $225M |
| Retained earnings | -$31.3M | -$77.7M | -$117M | -$137M | -$186M | -$293M | -$378M | -$466M | -$561M | -$649M |
| Shares (wtd avg diluted) | 65.7M | 608K | 9.08M | 15.3M | 25.6M | 41.3M | 46.9M | 53.2M | 71.0M | 88.1M |
Every figure is extracted from Altimmune, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.